5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.

@article{Yeh20175YearSA,
  title={5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.},
  author={Robert W Yeh and Sigmund Silber and Lianglong Chen and Shaoliang Chen and Shirish M S Hiremath and F. J. Neumann and Shubin Qiao and Shigeru Saito and Bo Xu and Yuejin Yang and Laura Mauri},
  journal={JACC. Cardiovascular interventions},
  year={2017},
  volume={10 3},
  pages={247-254}
}
OBJECTIVES The authors evaluated the 5-year cumulative incidence of cardiovascular events following Resolute zotarolimus-eluting stent (R-ZES) implantation. BACKGROUND Individual trials are often underpowered to show differences for low-frequency adverse events. The R-ZES was studied in 10 prospective clinical trials, designed with identical adverse event definitions, ascertainment, and adjudication. METHODS The RESOLUTE Global Clinical Trial Program includes 7,618 patients treated with R… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS